APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurodegenerative Disease CDMO

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Neurodegenerative Disease CDMO Market Analysis and Forecast 2026-2032

16 April 2026258 pages

Choose your research edition.

Industry ResearchNeurodegenerative Disease CDMO Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurodegenerative Disease CDMO Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Neurodegenerative Disease CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurodegenerative Disease CDMO Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Neurodegenerative Disease CDMO Market Analysis and Forecast 2026-2032258 pages · $4,950 USD

Market perspective

The global Neurodegenerative Disease CDMO market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Neurodegenerative Disease CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Neurodegenerative Disease CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Neurodegenerative Disease CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Neurodegenerative Disease CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Neurodegenerative Disease CDMO include AC Immune, Alterity Therapeutics, Biogen, Charles River Laboratories, Coave Therapeutics, Sysmex Corp, Donanemab, Eisai and Fujirebio Holdings, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Neurodegenerative Disease CDMO, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Neurodegenerative Disease CDMO, also provides the revenue of main regions and countries. Of the upcoming market potential for Neurodegenerative Disease CDMO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neurodegenerative Disease CDMO revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Neurodegenerative Disease CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Neurodegenerative Disease CDMO revenue, projected growth trends, production technology, application and end-user industry.

Neurodegenerative Disease CDMO Segment by Company

AC Immune

Alterity Therapeutics

Biogen

Charles River Laboratories

Coave Therapeutics

Sysmex Corp

Donanemab

Eisai

Fujirebio Holdings

GenSight Biologics

Neuropore Therapies

Nevrargenics

PPD

Samsung Biologics

Sanofi(Vigil Neuroscience)

Neurodegenerative Disease CDMO Segment by Type

Small Molecule Drug CDMO

Biopharmaceutical CDMO

Cell and Gene Therapy (CGT) CDMO

OtherS

Neurodegenerative Disease CDMO Segment by Application

Alzheimer's Disease

Parkinson's Disease

Huntington's Disease

Amyotrophic Lateral Sclerosis (ALS)

Multiple System Atrophy (MSA)

Progressive Supranuclear Palsy (PSP)

Others

Neurodegenerative Disease CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Disease CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Disease CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Disease CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Neurodegenerative Disease CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Neurodegenerative Disease CDMO company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neurodegenerative Disease CDMO revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neurodegenerative Disease CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Small Molecule Drug CDMO Major Player Table 3. Biopharmaceutical CDMO Major Player Table 4. Cell and Gene Therapy (CGT) CDMO Major Player Table 5. OtherS Major Player Table 6. Global Neurodegenerative Disease CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Alzheimer's Disease Major Player Table 8. Parkinson's Disease Major Player Table 9. Huntington's Disease Major Player Table 10. Amyotrophic Lateral Sclerosis (ALS) Major Player Table 11. Multiple System Atrophy (MSA) Major Player Table 12. Progressive Supranuclear Palsy (PSP) Major Player Table 13. Others Major Player Table 14. Neurodegenerative Disease CDMO Industry Trends Table 15. Neurodegenerative Disease CDMO Industry Drivers Table 16. Neurodegenerative Disease CDMO Industry Opportunities and Challenges Table 17. Neurodegenerative Disease CDMO Industry Restraints Table 18. Global Neurodegenerative Disease CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 19. Global Neurodegenerative Disease CDMO Market Size by Region (2021-2026) & (US$ Million) Table 20. Global Neurodegenerative Disease CDMO Market Share by Region (2021-2026) Table 21. Global Neurodegenerative Disease CDMO Market Size by Region (2027-2032) & (US$ Million) Table 22. Global Neurodegenerative Disease CDMO Market Share by Region (2027-2032) Table 23. Global Neurodegenerative Disease CDMO Revenue by Players (US$ Million) & (2021-2026) Table 24. Global Neurodegenerative Disease CDMO Revenue Market Share by Players (2021-2026) Table 25. Global Neurodegenerative Disease CDMO Key Players Ranking, 2024 VS 2025 VS 2026 Table 26. Global Neurodegenerative Disease CDMO Key Players Headquarters & Area Served Table 27. Global Neurodegenerative Disease CDMO Players, Product Type & Application Table 28. Global Neurodegenerative Disease CDMO Players Establishment Date Table 29. Global Players Market Concentration Ratio (CR5 and HHI) Table 30. Global Neurodegenerative Disease CDMO by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 31. Global Neurodegenerative Disease CDMO Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Neurodegenerative Disease CDMO Revenue by Type (2021-2026) & (US$ Million) Table 33. Global Neurodegenerative Disease CDMO Revenue by Type (2027-2032) & (US$ Million) Table 34. Global Neurodegenerative Disease CDMO Revenue Market Share by Type (2021-2026) Table 35. Global Neurodegenerative Disease CDMO Revenue Market Share by Type (2027-2032) Table 36. Global Neurodegenerative Disease CDMO Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Neurodegenerative Disease CDMO Revenue by Application (2021-2026) & (US$ Million) Table 38. Global Neurodegenerative Disease CDMO Revenue by Application (2027-2032) & (US$ Million) Table 39. Global Neurodegenerative Disease CDMO Revenue Market Share by Application (2021-2026) Table 40. Global Neurodegenerative Disease CDMO Revenue Market Share by Application (2027-2032) Table 41. AC Immune Company Information Table 42. AC Immune Business Overview Table 43. AC Immune Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. AC Immune Neurodegenerative Disease CDMO Product Portfolio Table 45. AC Immune Recent Development Table 46. Alterity Therapeutics Company Information Table 47. Alterity Therapeutics Business Overview Table 48. Alterity Therapeutics Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Alterity Therapeutics Neurodegenerative Disease CDMO Product Portfolio Table 50. Alterity Therapeutics Recent Development Table 51. Biogen Company Information Table 52. Biogen Business Overview Table 53. Biogen Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Biogen Neurodegenerative Disease CDMO Product Portfolio Table 55. Biogen Recent Development Table 56. Charles River Laboratories Company Information Table 57. Charles River Laboratories Business Overview Table 58. Charles River Laboratories Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Charles River Laboratories Neurodegenerative Disease CDMO Product Portfolio Table 60. Charles River Laboratories Recent Development Table 61. Coave Therapeutics Company Information Table 62. Coave Therapeutics Business Overview Table 63. Coave Therapeutics Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Coave Therapeutics Neurodegenerative Disease CDMO Product Portfolio Table 65. Coave Therapeutics Recent Development Table 66. Sysmex Corp Company Information Table 67. Sysmex Corp Business Overview Table 68. Sysmex Corp Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Sysmex Corp Neurodegenerative Disease CDMO Product Portfolio Table 70. Sysmex Corp Recent Development Table 71. Donanemab Company Information Table 72. Donanemab Business Overview Table 73. Donanemab Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Donanemab Neurodegenerative Disease CDMO Product Portfolio Table 75. Donanemab Recent Development Table 76. Eisai Company Information Table 77. Eisai Business Overview Table 78. Eisai Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Eisai Neurodegenerative Disease CDMO Product Portfolio Table 80. Eisai Recent Development Table 81. Fujirebio Holdings Company Information Table 82. Fujirebio Holdings Business Overview Table 83. Fujirebio Holdings Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Fujirebio Holdings Neurodegenerative Disease CDMO Product Portfolio Table 85. Fujirebio Holdings Recent Development Table 86. GenSight Biologics Company Information Table 87. GenSight Biologics Business Overview Table 88. GenSight Biologics Neurodegenerative Disease CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. GenSight Biologics Neurodegenerative Disease CDMO Product Portfolio Table 90. GenSight Biologics Recent Development Table 91. Neuropore Therapies Company Information Table 92. Neuropore Therapies Business Overview Table 93. Neuropore Therapies Neurodegenerative Disease CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Neuropore Therapies Neurodegenerative Disease CDMO Product Portfolio Table 95. Neuropore Therapies Recent Development Table 96. Nevrargenics Company Information Table 97. Nevrargenics Business Overview Table 98. Nevrargenics Neurodegenerative Disease CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Nevrargenics Neurodegenerative Disease CDMO Product Portfolio Table 100. Nevrargenics Recent Development Table 101. PPD Company Information Table 102. PPD Business Overview Table 103. PPD Neurodegenerative Disease CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. PPD Neurodegenerative Disease CDMO Product Portfolio Table 105. PPD Recent Development Table 106. Samsung Biologics Company Information Table 107. Samsung Biologics Business Overview Table 108. Samsung Biologics Neurodegenerative Disease CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Samsung Biologics Neurodegenerative Disease CDMO Product Portfolio Table 110. Samsung Biologics Recent Development Table 111. Sanofi(Vigil Neuroscience) Company Information Table 112. Sanofi(Vigil Neuroscience) Business Overview Table 113. Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Product Portfolio Table 115. Sanofi(Vigil Neuroscience) Recent Development Table 116. North America Neurodegenerative Disease CDMO Revenue by Type (2021-2026) & (US$ Million) Table 117. North America Neurodegenerative Disease CDMO Revenue by Type (2027-2032) & (US$ Million) Table 118. North America Neurodegenerative Disease CDMO Revenue by Application (2021-2026) & (US$ Million) Table 119. North America Neurodegenerative Disease CDMO Revenue by Application (2027-2032) & (US$ Million) Table 120. North America Neurodegenerative Disease CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. North America Neurodegenerative Disease CDMO Revenue by Country (2021-2026) & (US$ Million) Table 122. North America Neurodegenerative Disease CDMO Revenue by Country (US$ Million) & (2027-2032) Table 123. Europe Neurodegenerative Disease CDMO Revenue by Type (2021-2026) & (US$ Million) Table 124. Europe Neurodegenerative Disease CDMO Revenue by Type (2027-2032) & (US$ Million) Table 125. Europe Neurodegenerative Disease CDMO Revenue by Application (2021-2026) & (US$ Million) Table 126. Europe Neurodegenerative Disease CDMO Revenue by Application (2027-2032) & (US$ Million) Table 127. Europe Neurodegenerative Disease CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 128. Europe Neurodegenerative Disease CDMO Revenue by Country (2021-2026) & (US$ Million) Table 129. Europe Neurodegenerative Disease CDMO Revenue by Country (US$ Million) & (2027-2032) Table 130. China Neurodegenerative Disease CDMO Revenue by Type (2021-2026) & (US$ Million) Table 131. China Neurodegenerative Disease CDMO Revenue by Type (2027-2032) & (US$ Million) Table 132. China Neurodegenerative Disease CDMO Revenue by Application (2021-2026) & (US$ Million) Table 133. China Neurodegenerative Disease CDMO Revenue by Application (2027-2032) & (US$ Million) Table 134. Asia Neurodegenerative Disease CDMO Revenue by Type (2021-2026) & (US$ Million) Table 135. Asia Neurodegenerative Disease CDMO Revenue by Type (2027-2032) & (US$ Million) Table 136. Asia Neurodegenerative Disease CDMO Revenue by Application (2021-2026) & (US$ Million) Table 137. Asia Neurodegenerative Disease CDMO Revenue by Application (2027-2032) & (US$ Million) Table 138. Asia Neurodegenerative Disease CDMO Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 139. Asia Neurodegenerative Disease CDMO Revenue by Region (US$ Million) & (2021-2026) Table 140. Asia Neurodegenerative Disease CDMO Revenue by Region (US$ Million) & (2027-2032) Table 141. SAMEA Neurodegenerative Disease CDMO Revenue by Type (2021-2026) & (US$ Million) Table 142. SAMEA Neurodegenerative Disease CDMO Revenue by Type (2027-2032) & (US$ Million) Table 143. SAMEA Neurodegenerative Disease CDMO Revenue by Application (2021-2026) & (US$ Million) Table 144. SAMEA Neurodegenerative Disease CDMO Revenue by Application (2027-2032) & (US$ Million) Table 145. SAMEA Neurodegenerative Disease CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 146. SAMEA Neurodegenerative Disease CDMO Revenue by Country (2021-2026) & (US$ Million) Table 147. SAMEA Neurodegenerative Disease CDMO Revenue by Country (US$ Million) & (2027-2032) Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. Neurodegenerative Disease CDMO Image Figure 2. Global Neurodegenerative Disease CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurodegenerative Disease CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 4. Small Molecule Drug CDMO Image Figure 5. Biopharmaceutical CDMO Image Figure 6. Cell and Gene Therapy (CGT) CDMO Image Figure 7. OtherS Image Figure 8. Global Neurodegenerative Disease CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Neurodegenerative Disease CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 10. Alzheimer's Disease Image Figure 11. Parkinson's Disease Image Figure 12. Huntington's Disease Image Figure 13. Amyotrophic Lateral Sclerosis (ALS) Image Figure 14. Multiple System Atrophy (MSA) Image Figure 15. Progressive Supranuclear Palsy (PSP) Image Figure 16. Others Image Figure 17. Global Neurodegenerative Disease CDMO Market Size (US$ Million) & (2021-2032) Figure 18. Global Neurodegenerative Disease CDMO Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 19. Global Neurodegenerative Disease CDMO Market Share by Region: 2021 VS 2025 VS 2032 Figure 20. Global Neurodegenerative Disease CDMO Players Revenue Share Top 10 and Top 5 in 2025 Figure 21. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Neurodegenerative Disease CDMO Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Neurodegenerative Disease CDMO Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Neurodegenerative Disease CDMO Revenue Market Share by Type (2021-2032) Figure 25. Global Neurodegenerative Disease CDMO Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Neurodegenerative Disease CDMO Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 27. Global Neurodegenerative Disease CDMO Revenue Market Share by Application (2021-2032) Figure 28. North America Neurodegenerative Disease CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. North America Neurodegenerative Disease CDMO Revenue Share by Type (2021-2032) Figure 30. North America Neurodegenerative Disease CDMO Revenue Share by Application (2021-2032) Figure 31. North America Neurodegenerative Disease CDMO Revenue Share by Country (2021-2032) Figure 32. United States Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Canada Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Mexico Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Europe Neurodegenerative Disease CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 36. Europe Neurodegenerative Disease CDMO Revenue Share by Type (2021-2032) Figure 37. Europe Neurodegenerative Disease CDMO Revenue Share by Application (2021-2032) Figure 38. Europe Neurodegenerative Disease CDMO Revenue Share by Country (2021-2032) Figure 39. Germany Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. France Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. U.K. Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Italy Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Spain Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Russia Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Netherlands Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. Nordic Countries Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 47. China Neurodegenerative Disease CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. China Neurodegenerative Disease CDMO Revenue Share by Type (2021-2032) Figure 49. China Neurodegenerative Disease CDMO Revenue Share by Application (2021-2032) Figure 50. Asia Neurodegenerative Disease CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 51. Asia Neurodegenerative Disease CDMO Revenue Share by Type (2021-2032) Figure 52. Asia Neurodegenerative Disease CDMO Revenue Share by Application (2021-2032) Figure 53. Asia Neurodegenerative Disease CDMO Revenue Share by Region (2021-2032) Figure 54. Japan Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. South Korea Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. India Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Australia Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Taiwan Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Southeast Asia Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. SAMEA Neurodegenerative Disease CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 61. SAMEA Neurodegenerative Disease CDMO Revenue Share by Type (2021-2032) Figure 62. SAMEA Neurodegenerative Disease CDMO Revenue Share by Application (2021-2032) Figure 63. SAMEA Neurodegenerative Disease CDMO Revenue Share by Country (2021-2032) Figure 64. Brazil Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Argentina Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Chile Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Colombia Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Peru Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Saudi Arabia Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Israel Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. UAE Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Turkey Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Iran Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Egypt Neurodegenerative Disease CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Small Molecule Drug CDMO
  • Biopharmaceutical CDMO
  • Cell and Gene Therapy (CGT) CDMO
  • OtherS
Applications
  • Alzheimer's Disease
  • Parkinson's Disease
  • Huntington's Disease
  • Amyotrophic Lateral Sclerosis (ALS)
  • Multiple System Atrophy (MSA)
  • Progressive Supranuclear Palsy (PSP)
  • Others
Companies covered
  • AC Immune
  • Alterity Therapeutics
  • Biogen
  • Charles River Laboratories
  • Coave Therapeutics
  • Sysmex Corp
  • Donanemab
  • Eisai
  • Fujirebio Holdings
  • GenSight Biologics
  • Neuropore Therapies
  • Nevrargenics
  • PPD
  • Samsung Biologics
  • Sanofi(Vigil Neuroscience)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Neurodegenerative Disease CDMO Market by Type
  3. 1.2.1 Global Neurodegenerative Disease CDMO Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Small Molecule Drug CDMO
  5. 1.2.3 Biopharmaceutical CDMO
  6. 1.2.4 Cell and Gene Therapy (CGT) CDMO
  7. 1.2.5 OtherS
  8. 1.3 Neurodegenerative Disease CDMO Market by Application
  9. 1.3.1 Global Neurodegenerative Disease CDMO Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Alzheimer's Disease
  11. 1.3.3 Parkinson's Disease
  12. 1.3.4 Huntington's Disease
  13. 1.3.5 Amyotrophic Lateral Sclerosis (ALS)
  14. 1.3.6 Multiple System Atrophy (MSA)
  15. 1.3.7 Progressive Supranuclear Palsy (PSP)
  16. 1.3.8 Others
  17. 1.4 Assumptions and Limitations
  18. 1.5 Study Goals and Objectives
2 Neurodegenerative Disease CDMO Market Dynamics
  1. 2.1 Neurodegenerative Disease CDMO Industry Trends
  2. 2.2 Neurodegenerative Disease CDMO Industry Drivers
  3. 2.3 Neurodegenerative Disease CDMO Industry Opportunities and Challenges
  4. 2.4 Neurodegenerative Disease CDMO Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Neurodegenerative Disease CDMO Market Perspective (2021-2032)
  2. 3.2 Global Neurodegenerative Disease CDMO Growth Trends by Region
  3. 3.2.1 Global Neurodegenerative Disease CDMO Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Neurodegenerative Disease CDMO Market Size by Region (2021-2026)
  5. 3.2.3 Global Neurodegenerative Disease CDMO Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Neurodegenerative Disease CDMO Revenue by Players
  2. 4.1.1 Global Neurodegenerative Disease CDMO Revenue by Players (2021-2026)
  3. 4.1.2 Global Neurodegenerative Disease CDMO Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Neurodegenerative Disease CDMO Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Neurodegenerative Disease CDMO Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Neurodegenerative Disease CDMO Key Players Headquarters & Area Served
  7. 4.4 Global Neurodegenerative Disease CDMO Players, Product Type & Application
  8. 4.5 Global Neurodegenerative Disease CDMO Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Neurodegenerative Disease CDMO Market CR5 and HHI
  11. 4.6.3 2025 Neurodegenerative Disease CDMO Tier 1, Tier 2, and Tier 3
5 Neurodegenerative Disease CDMO Market Size by Type
  1. 5.1 Global Neurodegenerative Disease CDMO Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Neurodegenerative Disease CDMO Revenue by Type (2021-2032)
  3. 5.3 Global Neurodegenerative Disease CDMO Revenue Market Share by Type (2021-2032)
6 Neurodegenerative Disease CDMO Market Size by Application
  1. 6.1 Global Neurodegenerative Disease CDMO Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Neurodegenerative Disease CDMO Revenue by Application (2021-2032)
  3. 6.3 Global Neurodegenerative Disease CDMO Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 AC Immune
  2. 7.1.1 AC Immune Company Information
  3. 7.1.2 AC Immune Business Overview
  4. 7.1.3 AC Immune Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  5. 7.1.4 AC Immune Neurodegenerative Disease CDMO Product Portfolio
  6. 7.1.5 AC Immune Recent Developments
  7. 7.2 Alterity Therapeutics
  8. 7.2.1 Alterity Therapeutics Company Information
  9. 7.2.2 Alterity Therapeutics Business Overview
  10. 7.2.3 Alterity Therapeutics Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Alterity Therapeutics Neurodegenerative Disease CDMO Product Portfolio
  12. 7.2.5 Alterity Therapeutics Recent Developments
  13. 7.3 Biogen
  14. 7.3.1 Biogen Company Information
  15. 7.3.2 Biogen Business Overview
  16. 7.3.3 Biogen Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Biogen Neurodegenerative Disease CDMO Product Portfolio
  18. 7.3.5 Biogen Recent Developments
  19. 7.4 Charles River Laboratories
  20. 7.4.1 Charles River Laboratories Company Information
  21. 7.4.2 Charles River Laboratories Business Overview
  22. 7.4.3 Charles River Laboratories Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Charles River Laboratories Neurodegenerative Disease CDMO Product Portfolio
  24. 7.4.5 Charles River Laboratories Recent Developments
  25. 7.5 Coave Therapeutics
  26. 7.5.1 Coave Therapeutics Company Information
  27. 7.5.2 Coave Therapeutics Business Overview
  28. 7.5.3 Coave Therapeutics Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Coave Therapeutics Neurodegenerative Disease CDMO Product Portfolio
  30. 7.5.5 Coave Therapeutics Recent Developments
  31. 7.6 Sysmex Corp
  32. 7.6.1 Sysmex Corp Company Information
  33. 7.6.2 Sysmex Corp Business Overview
  34. 7.6.3 Sysmex Corp Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Sysmex Corp Neurodegenerative Disease CDMO Product Portfolio
  36. 7.6.5 Sysmex Corp Recent Developments
  37. 7.7 Donanemab
  38. 7.7.1 Donanemab Company Information
  39. 7.7.2 Donanemab Business Overview
  40. 7.7.3 Donanemab Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Donanemab Neurodegenerative Disease CDMO Product Portfolio
  42. 7.7.5 Donanemab Recent Developments
  43. 7.8 Eisai
  44. 7.8.1 Eisai Company Information
  45. 7.8.2 Eisai Business Overview
  46. 7.8.3 Eisai Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Eisai Neurodegenerative Disease CDMO Product Portfolio
  48. 7.8.5 Eisai Recent Developments
  49. 7.9 Fujirebio Holdings
  50. 7.9.1 Fujirebio Holdings Company Information
  51. 7.9.2 Fujirebio Holdings Business Overview
  52. 7.9.3 Fujirebio Holdings Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Fujirebio Holdings Neurodegenerative Disease CDMO Product Portfolio
  54. 7.9.5 Fujirebio Holdings Recent Developments
  55. 7.10 GenSight Biologics
  56. 7.10.1 GenSight Biologics Company Information
  57. 7.10.2 GenSight Biologics Business Overview
  58. 7.10.3 GenSight Biologics Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  59. 7.10.4 GenSight Biologics Neurodegenerative Disease CDMO Product Portfolio
  60. 7.10.5 GenSight Biologics Recent Developments
  61. 7.11 Neuropore Therapies
  62. 7.11.1 Neuropore Therapies Company Information
  63. 7.11.2 Neuropore Therapies Business Overview
  64. 7.11.3 Neuropore Therapies Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Neuropore Therapies Neurodegenerative Disease CDMO Product Portfolio
  66. 7.11.5 Neuropore Therapies Recent Developments
  67. 7.12 Nevrargenics
  68. 7.12.1 Nevrargenics Company Information
  69. 7.12.2 Nevrargenics Business Overview
  70. 7.12.3 Nevrargenics Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Nevrargenics Neurodegenerative Disease CDMO Product Portfolio
  72. 7.12.5 Nevrargenics Recent Developments
  73. 7.13 PPD
  74. 7.13.1 PPD Company Information
  75. 7.13.2 PPD Business Overview
  76. 7.13.3 PPD Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  77. 7.13.4 PPD Neurodegenerative Disease CDMO Product Portfolio
  78. 7.13.5 PPD Recent Developments
  79. 7.14 Samsung Biologics
  80. 7.14.1 Samsung Biologics Company Information
  81. 7.14.2 Samsung Biologics Business Overview
  82. 7.14.3 Samsung Biologics Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Samsung Biologics Neurodegenerative Disease CDMO Product Portfolio
  84. 7.14.5 Samsung Biologics Recent Developments
  85. 7.15 Sanofi(Vigil Neuroscience)
  86. 7.15.1 Sanofi(Vigil Neuroscience) Company Information
  87. 7.15.2 Sanofi(Vigil Neuroscience) Business Overview
  88. 7.15.3 Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Product Portfolio
  90. 7.15.5 Sanofi(Vigil Neuroscience) Recent Developments
8 North America
  1. 8.1 North America Neurodegenerative Disease CDMO Revenue (2021-2032)
  2. 8.2 North America Neurodegenerative Disease CDMO Revenue by Type (2021-2032)
  3. 8.2.1 North America Neurodegenerative Disease CDMO Revenue by Type (2021-2026)
  4. 8.2.2 North America Neurodegenerative Disease CDMO Revenue by Type (2027-2032)
  5. 8.3 North America Neurodegenerative Disease CDMO Revenue Share by Type (2021-2032)
  6. 8.4 North America Neurodegenerative Disease CDMO Revenue by Application (2021-2032)
  7. 8.4.1 North America Neurodegenerative Disease CDMO Revenue by Application (2021-2026)
  8. 8.4.2 North America Neurodegenerative Disease CDMO Revenue by Application (2027-2032)
  9. 8.5 North America Neurodegenerative Disease CDMO Revenue Share by Application (2021-2032)
  10. 8.6 North America Neurodegenerative Disease CDMO Revenue by Country
  11. 8.6.1 North America Neurodegenerative Disease CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Neurodegenerative Disease CDMO Revenue by Country (2021-2026)
  13. 8.6.3 North America Neurodegenerative Disease CDMO Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Neurodegenerative Disease CDMO Revenue (2021-2032)
  2. 9.2 Europe Neurodegenerative Disease CDMO Revenue by Type (2021-2032)
  3. 9.2.1 Europe Neurodegenerative Disease CDMO Revenue by Type (2021-2026)
  4. 9.2.2 Europe Neurodegenerative Disease CDMO Revenue by Type (2027-2032)
  5. 9.3 Europe Neurodegenerative Disease CDMO Revenue Share by Type (2021-2032)
  6. 9.4 Europe Neurodegenerative Disease CDMO Revenue by Application (2021-2032)
  7. 9.4.1 Europe Neurodegenerative Disease CDMO Revenue by Application (2021-2026)
  8. 9.4.2 Europe Neurodegenerative Disease CDMO Revenue by Application (2027-2032)
  9. 9.5 Europe Neurodegenerative Disease CDMO Revenue Share by Application (2021-2032)
  10. 9.6 Europe Neurodegenerative Disease CDMO Revenue by Country
  11. 9.6.1 Europe Neurodegenerative Disease CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Neurodegenerative Disease CDMO Revenue by Country (2021-2026)
  13. 9.6.3 Europe Neurodegenerative Disease CDMO Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Neurodegenerative Disease CDMO Revenue (2021-2032)
  2. 10.2 China Neurodegenerative Disease CDMO Revenue by Type (2021-2032)
  3. 10.2.1 China Neurodegenerative Disease CDMO Revenue by Type (2021-2026)
  4. 10.2.2 China Neurodegenerative Disease CDMO Revenue by Type (2027-2032)
  5. 10.3 China Neurodegenerative Disease CDMO Revenue Share by Type (2021-2032)
  6. 10.4 China Neurodegenerative Disease CDMO Revenue by Application (2021-2032)
  7. 10.4.1 China Neurodegenerative Disease CDMO Revenue by Application (2021-2026)
  8. 10.4.2 China Neurodegenerative Disease CDMO Revenue by Application (2027-2032)
  9. 10.5 China Neurodegenerative Disease CDMO Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Neurodegenerative Disease CDMO Revenue (2021-2032)
  2. 11.2 Asia Neurodegenerative Disease CDMO Revenue by Type (2021-2032)
  3. 11.2.1 Asia Neurodegenerative Disease CDMO Revenue by Type (2021-2026)
  4. 11.2.2 Asia Neurodegenerative Disease CDMO Revenue by Type (2027-2032)
  5. 11.3 Asia Neurodegenerative Disease CDMO Revenue Share by Type (2021-2032)
  6. 11.4 Asia Neurodegenerative Disease CDMO Revenue by Application (2021-2032)
  7. 11.4.1 Asia Neurodegenerative Disease CDMO Revenue by Application (2021-2026)
  8. 11.4.2 Asia Neurodegenerative Disease CDMO Revenue by Application (2027-2032)
  9. 11.5 Asia Neurodegenerative Disease CDMO Revenue Share by Application (2021-2032)
  10. 11.6 Asia Neurodegenerative Disease CDMO Revenue by Country
  11. 11.6.1 Asia Neurodegenerative Disease CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Neurodegenerative Disease CDMO Revenue by Country (2021-2026)
  13. 11.6.3 Asia Neurodegenerative Disease CDMO Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Neurodegenerative Disease CDMO Revenue (2021-2032)
  2. 12.2 SAMEA Neurodegenerative Disease CDMO Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Neurodegenerative Disease CDMO Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Neurodegenerative Disease CDMO Revenue by Type (2027-2032)
  5. 12.3 SAMEA Neurodegenerative Disease CDMO Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Neurodegenerative Disease CDMO Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Neurodegenerative Disease CDMO Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Neurodegenerative Disease CDMO Revenue by Application (2027-2032)
  9. 12.5 SAMEA Neurodegenerative Disease CDMO Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Neurodegenerative Disease CDMO Revenue by Country
  11. 12.6.1 SAMEA Neurodegenerative Disease CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Neurodegenerative Disease CDMO Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Neurodegenerative Disease CDMO Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst